论文部分内容阅读
112例早期糖尿病肾病合并高脂血症患者随机分为治疗组使用普伐他汀10mg/天,连续6个月,对照组其余各项治疗措施相同,结果①治疗组第3月末血Ch和LDL较治疗前及对照组均有显著降低(P<0.05),第6月末较第3月末时无显著性降低(P>0.05);②治疗组第3月末UAE及UAE/Cr比较治疗前及对照组均有显著降低(P<0.01),第6月末较第3月末时仍有进一步降低,其差异有显著性(P<0.05)。内生肌酐清除率变化不显著(P>0.05)。③血浆Ch及LDL与UAE、UAE/Cr有显著的正相关关系。结论:普伐他汀不仅能有效降低血脂,还对早期糖尿病肾病有改善作用。
112 cases of early diabetic nephropathy with hyperlipidemia were randomly divided into treatment group treated with pravastatin 10mg / day for 6 months, the control group the rest of the treatment measures the same results ① the end of the third month of treatment group blood Ch and LDL The levels of UAE and UAE / Cr at the end of the third month in the treatment group were significantly lower than those before the treatment and in the control group (P <0.05), but not significantly lower at the end of the sixth month than the end of the third month (P> 0.05) (P <0.01). The end of June was lower than the end of the third month, the difference was significant (P <0.05). Endogenous creatinine clearance rate did not change significantly (P> 0.05). Plasma Ch and LDL had significant positive correlation with UAE and UAE / Cr. Conclusion: Pravastatin can not only reduce blood lipids, but also improve early diabetic nephropathy.